Why and how we should treat elderly patients with hypertension?

Current Vascular Pharmacology

Volumn 8, Issue 6, 2010, Pages 780-787

  Aronow, Wilbert S ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Angiotensin receptor blockers; Angiotensin converting enzyme inhibitors; Antihypertensive drug therapy; Beta blockers; Calcium channel blockers; Diuretics; Elderly; Hypertension

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BENAZEPRIL; BENAZEPRIL PLUS HYDROCHLOROTHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CHLORTALIDONE; CLONIDINE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; GUANETHIDINE; HYDRALAZINE; HYDROCHLOROTHIAZIDE; INDAPAMIDE; INDAPAMIDE PLUS PERINDOPRIL; MINOXIDIL; NITRENDIPINE; PERINDOPRIL; PLACEBO; RESERPINE; TRANDOLAPRIL PLUS VERAPAMIL; VERAPAMIL;

ADD ON THERAPY; ANGINA PECTORIS; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; COGNITIVE DEFECT; CONSTIPATION; DEMENTIA; DEPRESSION; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DRUG TOLERABILITY; FLUID RETENTION; FOLLOW UP; HEADACHE; HEART FAILURE; HIRSUTISM; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; LUPUS LIKE SYNDROME; MORTALITY; PATHOPHYSIOLOGY; PERICARDIAL EFFUSION; PREVALENCE; SEDATION; SIDE EFFECT; STROKE; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; TREATMENT RESPONSE; WEIGHT REDUCTION;

EID: 78049388638     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016110793563933     Document Type: Article

References (115)

1. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report ofthe Joint National Committee on Prevention, Detection, Evaluation,and Treatment of High Blood Pressure. The JNC 7 Report. JAMA 2003; 289: 2560-72.
2. Waeber B, Banegas JR, Mancia G, Ruilope LM. Blood pressurecontrol based on office and ambulatory blood pressure monitoring:the European experience in hypertensive patients treated in clinicalpractice. Arch Med Sci 2009; 5: 351-8.
3. Lakatta EG. Mechanisms of hypertension in the elderly. J AmGeriatr Soc 1989; 37: 780-90.
4. Gribbin B, Pickering GT, Sleight P, Peto R. Effect of age and highblood pressure on baroreflex sensitivity in man. Circ Res 1971; 29:424-31.
5. Aronow WS. Dizziness and syncope. In: Hazzard WR, Blass JP,Ettinger WH Jr, Halter JB, Ouslander JG, Eds. Principles of GeriatricMedicine and Gerontology, 4th ed. New York City: McGraw-Hill, Inc., 1998; pp. 1519-34.
6. Joseph J, Koka M, Aronow WS. Prevalence of moderate and severerenal insufficiency in older persons with hypertension, diabetesmellitus, coronary artery disease, peripheral arterial disease,ischemic stroke, or congestive heart failure in an academic nursinghome. J Am Med Dir Assoc 2008; 9: 257-9.
7. Chiong JR, Aronow WS, Khan IA, et al. Secondary hypertension:current diagnosis and treatment. International J Cardiol 2008; 124:6-21.
8. Alcazar JM, Garcia-Donaire JA, Rodicio JL. Atherosclerotic renovasculardisease: detection and therapeutic intervention. Arch MedSci 2009; 5: 372-7.
9. Cifkova R. Epidemiology and risk of hypertension. Arch Med Sci 2009; 5: 199-211.
10. Lloyd-Jones D, Adams R, Carnethon M., et al. Heart disease andstroke statistics-2009 update: a report from the American HeartAssociation Statistics Committee and Stroke Statistics Subcommittee.Circulation 2009; 119: e21-e181.
11. Vasan RS, Larson MG, Leip EP, et al. Impact of high-normalblood pressure on the risk of cardiovascular disease. N Engl J Med 2001; 345: 1291-7.
12. Mendelson G, Ness J, Aronow WS. Drug treatment of hypertensionin older persons in an academic hospital-based geriatrics practice. JAm Geriatr Soc 1999; 47: 597-9.
13. Aronow WS, Ahn C, Gutstein H. Prevalence and incidence ofcardiovascular disease in 1160 older men and 2464 older women ina long-term health care facility. J Gerontol Med Sci 2002; 57A:M45-M46.
14. Koka M, Joseph J, Aronow WS. Adequacy of control of hypertensionin an academic nursing home. J Am Med Dir Assoc 2007; 8:538-40.
15. Joseph J, Koka M, Aronow WS. Prevalence of a hemoglobin A1c<7.0%, of a blood pressure <130/80 mm Hg, and of a serum lowdensitylipoprotein cholesterol <100 mg/dl in older patients withdiabetes mellitus in an academic nursing home. J Am Med Dir Assoc 2008; 9: 51-4.
16. National High Blood Pressure Education Program Working Group.National High Blood Pressure Education Program working groupreport on hypertension in the elderly. Hypertension 1994; 23: 275-85.
17. Madhavan S, Ooi WL, Cohen H, Alderman MH. Relation of pulsepressure and blood pressure reduction to the incidence of myocardialinfarction. Hypertension 1994; 23: 395-401.
18. Rigaud A-S, Forette B. Hypertension in older adults. J GerontolMed Sci 2001; 56A: M217-M225.
19. Laurent S, Beaussler H, Collin C, Boutouyrie P. Large artery damagein hypertension. Arch Med Sci 2009; 5: 243-53.
20. Fried LP, Kronmal RA, Newman AB, et al. Risk factors for 5-yearmortality in older adults. The Cardiovascular Health Study. JAMA 1998; 279: 585-92.
21. Molander L, Lovheim H, Norman T, Nordstrom P, Gustafson Y.Lower systolic blood pressure is associated with greater mortalityin people aged 85 and older. J Am Geriatr Soc 2008; 56: 1853-9.
22. Aronow WS, Ahn C, Kronzon I, Koenigsberg M. Congestive heartfailure, coronary events and atherothrombotic brain infarction inelderly blacks and whites with systemic hypertension and with andwithout echocardiographic and electrocardiographic evidence ofleft ventricular hypertrophy. Am J Cardiol 1991; 67: 295-9.
23. Aronow WS, Ahn C. Risk factors for new coronary events in alarge cohort of very elderly patients with and without coronary arterydisease. Am J Cardiol 1996; 77: 864-6.
24. Vokonas PS, Kannel WB. Epidemiology of coronary heart diseasein the elderly. In Aronow WS, Fleg JL, Rich MW Eds: CardiovascularDisease in the Elderly, fourth edition, New York City, InformaHealthcare, 2008; pp. 215-41.
25. Franklin SS, Larson MG, Khan SA, et al. Does the relation ofblood pressure to coronary heart disease risk change with aging?The Framingham Heart Study. Circulation 2001; 103: 1245-9.
26. Psaty BM, Furberg CD, Kuller LH, et al. Association betweenblood pressure level and the risk of myocardial infarction, stroke,and total mortality: the cardiovascular health study. Arch InternMed 2001; 161: 1183-92.
27. Aronow WS, Ahn C, Gutstein H. Risk factors for newatherothrombotic brain infarction in 664 older men and 1,488 olderwomen. Am J Cardiol 1996; 77: 1381-3.
28. Aronow WS, Frishman WH. Treatment of hypertension and preventionof ischemic stroke. Curr Cardiol Rep 2004; 6: 124-9.
29. Wolf PA. Cerebrovascular disease in the elderly. In: Tresch DD,Aronow WS, Eds. Cardiovascular disease in the elderly patient. New York City: Marcel Dekker, Inc. 1994; pp. 125-47.
30. Aronow WS, Ahn C, Kronzon I. Comparison of incidences ofcongestive heart failure in older African-Americans, Hispanics, andwhites. Am J Cardiol 1999; 84: 611-2.
31. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KKL. The progressionfrom hypertension to congestive heart failure. JAMA 1996; 275: 1557-62.
32. Stokes J III, Kannel WB, Wolf PA, et al. The relative importanceof selected risk factors for various manifestations of cardiovasculardisease among men and women from 35 to 64 years old: 30 yearsof follow-up in the Framingham Study. Circulation 1987; 75(supplV): V-65-V-73.
33. Aronow WS, Sales FF, Etienne F, Lee NH. Prevalence of peripheralarterial disease and its correlation with risk factors for peripheralperipheralarterial disease in elderly patients in a long-term health care facility.Am J Cardiol 1988; 62: 644-6.
34. Ness J, Aronow WS, Ahn C. Risk factors for peripheral arterialdisease in an academic hospital-based geriatrics practice. J AmGeriatr Soc 2000; 48: 312-4.
35. Ness J, Aronow WS, Newkirk E, McDanel D. Prevalence of symptomaticperipheral arterial disease, modifiable risk factors, and appropriateuse of drugs in the treatment of peripheral arterial diseasein older persons seen in a university general medicine clinic. J GerontolMed Sci 2005; 60A: M255-M257.
36. Aronow WS, Ahmed MI, Ekundayo OJ, Allman RM, Lloyd-Jones DM, Ahmed A. A propensity-matched study of the association ofperipheral arterial disease with cardiovascular outcomes in community-dwelling older adults. Am J Cardiol 2009; 103: 130-5.
37. Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolledhypertension in the United States. N Engl J Med 2001; 345:479-86.
38. Gandelman G, Aronow WS, Varma R. Prevalence of adequateblood pressure control in self-pay or Medicare patients vs. Medicaidor private insurance patients with systemic hypertension followedin a university cardiology or general medicine clinic. Am JCardiol 2004; 94: 815-6.
39. Aronow WS, Banach M. Atrial fibrillation: the new epidemic of theageing world. J Atr Fibrillation 2009; 1: 337-61.
40. Aksnes TA, Kjeldsen SE, Julius S. Atrial fibrillation and hypertension. Arch Med Sci 2009; 5: 267-72.
41. Aronow WS, Ahn C, Kronzon I, Koenigsberg M. Congestive heartfailure, coronary events and atherothrombotic brain infarction inelderly blacks and whites with systemic hypertension and with andwithout echocardiographic and electrocardiographic evidence ofleft ventricular hypertrophy. Am J Cardiol 1991; 67: 295-9.
42. Wachtell K. Hypertensive heart disease: left ventricular hypertrophy.Arch Med Sci 2009; 5: 300-9.
43. Aronow WS. Hypertension and the older diabetic. Clin GeriatrMed 2008; 24: 489-501.
44. Nilsson PM. Diabetes and hypertension. Arch Med Sci 2009; 5:310-9.
45. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and managementof the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute scientific statement.Circulation 2005; 112: 2735-52.
46. Redon J, Martinez F, Fabia MJ. The metabolic syndrome in hypertension.Arch Med Sci 2009; 5: 320-9.
47. Bielecka-Dabrowa A, Michalska M, Rysz J, Banach M. Arterialhypertension in patients with coronary artery disease treated withcoronary artery bypass surgery. Arch Med Sci 2009; 5: 378-92.
48. Report by the Management Committee. The Australian TherapeuticTrial in Mild Hypertension. Lancet 1980; 1: 1261-7.
49. Medical Research Council Working Party. MRC trial of mild hypertension:principal results. Br Med J 1985; 291: 97-104.
50. MRC Working Party. Medical Research Council Trial of treatmentof hypertension in older adults: principal results. Br Med J 1992;304: 405-12.
51. Amery A, Birkenhager W, Brixko P, et al. Morbidity and mortalityresults from the European Working Party on High Blood Pressurein the Elderly Trial. Lancet 1985; 1: 1349-54.
52. Coope J, Warrender TS. Randomised trial of the treatment of hypertensionin elderly patients in primary care. Br Med J 1986; 293:1145-51.
53. Dahlof B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in OldPatients With Hypertension (STOP Hypertension). Lancet 1991;338: 1281-5.
54. SHEP Cooperative Research Group. Prevention of stroke by antihypertensivedrug treatment in older persons with isolated systolichypertension. Final results of the Systolic Hypertension in the ElderlyProgram (SHEP). JAMA 1991; 265: 3255-64.
55. Kostis JB, Davis BR, Cutler J, et al. Prevention of heart failure byantihypertensive drug treatment in older persons with isolated systolichypertension. JAMA 1997; 278: 212-6.
56. Perry HM Jr, Davis BR, Price TR, et al. Effect of treating isolatedsystolic hypertension on the risk of developing various types andsubtypes of stroke. The Systolic Hypertension in the Elderly Program(SHEP). JAMA 2000; 284: 465-71.
57. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blindcomparison of placebo and active treatment for older patients withisolated systolic hypertension. Lancet 1997; 350: 757-64.
58. Wang J-G, Staessen JA, Gong L, Liu L. Chinese trial on isolatedsystolic hypertension in the elderly. Arch Intern Med 2000; 160:211-20.
59. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertensionin patients 80 years of age or older. N Engl J Med 2008; 358: 1887-98.
60. Mcinnes G. Morbidity and mortality trials: black and white orshades of grey. Arch Med Sci 2009; 5: 282-93.
61. Aronow WS, Frishman WH. Effect of antihypertensive drug treatmenton cognitive function. Clin Geriatr 2006; 14: 25-8.
62. Progress Collaborative Group. Randomised trial of a perindoprilbasedblood-pressure-lowering regimen among 6105 individualswith previous stroke or transient ischaemic attack. Lancet 2001;358: 1033-41.
63. Forette F, Seux M-L, Staessen JA, et al. The prevention of dementiawith antihypertensive treatment. New evidence from the SystolicHypertension in Europe (Syst-Eur) study. Arch Intern Med 2002; 162: 2046-52.
64. Murray MD, Lane KA, Gao S, et al. Preservation of cognitivefunction with antihypertensive medications. A longitudinal analysisof a community-based sample of African Americans. Arch InternMed 2002; 162: 2090-6.
65. Veld BA, Ruitenberg A, Hofman A, Stricker BH, Breteler MM. Antihypertensive drugs and incidence of dementia: the RotterdamStudy. Neurobiol Aging 2001; 22: 407-12.
66. Saxby BK, Harrington F, Wesnes KA, McKeith IG, Ford GA.Candesartan and cognitive decline in older patients with hypertension:a substudy of the SCOPE trial. Neurology 2008; 70: 1858-66.
67. Peters R, Beckett N, Forette F, et al. Incident ementia and bloodpressure lowering in the Hypertension in the Very elderly Trialcognitive function assessment (HYVET-COG): a double-blind,placebo controlled trial. Lancet Neurol 2008; 7: 683-9.
68. Aronow WS. What is the appropriate treatment of hypertension inelders? (editorial). J Gerontol A Biol Sci Med Sci 2002; 57: M483-M486.
69. Goodwin JS. Embracing complexity: a consideration of hypertensionin the very old. J Gerontol: Med Sci 2003; 58A: M653-M658.
70. Aronow WS. Older age should not be a barrier to the treatment ofhypertension. Nat Clin Prac Cardiovasc Med 2008; 5: 514-5.
71. Mendelson G, Nassimiha D, Aronow WS. Simultaneous measurementsof blood pressures in right and left brachial arteries. CardiolRev 2004; 12: 276-8.
72. Nancia G, Seravalle G, Grassi G. Therapeutic strategies to lowerand control high blood pressure. Arch Med Sci 2009; 5: 294-9.
73. Erdine S, Viigimaa M. Compliance with treatment in hypertension.Arch Med Sci 2009; 5: 359-65.
74. Palmer BF. Renal dysfunction complicating the treatment of hypertension.N Engl J Med 2002; 347: 1256-61.
75. Hricik DE, Browning PJ, Kopelman R, Goorno WE, Madias NE, Dzau VJ. Captopril-induced functional renal insufficiencyin patientswith bilateral renal artery stenosis or renal artery stenosis in asolitary kidney. N Engl J Med 1983; 308: 373-6.
76. Toto RD, Mitchell HC, Lee HC, Milam C, Pettinger WA. Reversiblerenal insufficiency due to angiotensin-converting enzyme inhibitorsinhypertensive nephrosclerosis. Ann Intern Med 1991; 115:513-9.
77. Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertensionin the prevention and management of ischemic heart disease.A scientific statement from the American Heart Association Councilfor High Blood Pressure Research and the Councils on ClinicalCardiology and Epidemiology and Prevention. Circulation 2007;115: 2761-88.
78. Pahor M, Guralnik JM, Corti MC, et al. Long-term survival anduse of antihypertensive medications in older persons. J Am GeriatrSoc 1995; 43: 1191-7.
79. Aronow WS. Verapamil as an antiarrhythmic agent. Drug Treatmentof Cardiac Arrhythmias. In: Gould LA, Ed. Mount Kisco,New York: Futura Publishing Company, Inc., 1983; pp. 325-41.
80. The Multicenter Diltiazem Postinfarction Trial Research Group.The effect of diltiazem on mortality and reinfarction after myocardialinfarction. N Engl J Med 1988; 319: 385-92.
81. Goldstein RE, Boccuzzi SJ, Cruess D, Nattel S. Diltiazem increaseslate-onset congestive heart failure in postinfarction patients withearly reduction in ejection fraction. Circulation 1991; 83: 52-60.
82. Aronow WS, Ahn C. Incidence of new coronary events in olderpersons with prior myocardial infarction and systemic hypertensiontreated with beta blockers, angiotensin-converting enzyme inhibitors,diuretics, calcium antagonists, and alpha blockers. Am J Cardiol 2002; 89: 1207-9.
83. Elkayam U, Amin J, Mehra A, Vasquez J, Weber L, Rahimtoola SH. A prospective, randomized, double-blind, crossover study tocompare the efficacy and safety of chronic nifedipine therapy withthat of isosorbide dinitrate and their combination in the treatment ofchronic congestive heart failure. Circulation 1990; 82: 1954-61.
84. ALLHAT Officers and Coordinators for the ALLHAT CollaborativeResearch Group. Major cardiovascular events in hypertensivepatients randomized to doxazosin vs. chlorthalidone. The Antihypertensiveand Lipid-Lowering Treatment to Prevent Heart AttackTrial (ALLHAT). JAMA 2000; 283: 1967-75.
85. Frishman WH, Aronow WS, Cheng-Lai A. Cardiovascular drugtherapy in the elderly. In: Aronow WS, Fleg JL, Rich MW eds:Cardiovascular Disease in the Elderly, 4th ed, New York City, InformaHealthcare, 2008, pp 99-135.
86. Cameron HA, Ramsay LE. The lupus syndrome induced by hydralazine:a common complication with low dose treatment. Br Med J(Clin Res Ed) 1984; 289: 410-2.
87. Krehlik JM, Hindson DA, Crowley JJ Jr, Knight LL. Minoxidilassociatedpericarditis and fatal cardiac tamponade. West J Med 1986; 143: 527-9.
88. Ryan TJ, Antman EM, Brooks NH, et al. 1999 update: ACC/AHAguidelines for the management of patients with acute myocardialinfarction: executive summary and recommendations. A report ofthe American College of Cardiology/American Heart AssociationTask Force on Practice Guidelines (Committee on Management ofAcute Myocardial Infarction). Circulation 1999; 100: 1016-30.
89. Aronow WS, Ahn C. Effect of beta blockers on incidence of newcoronary events in older persons with prior myocardial infarctionand diabetes mellitus. Am J Cardiol 2001; 87: 780-1.
90. Aronow WS, Ahn C. Effect of beta blockers on incidence of newcoronary events in older persons with prior myocardial infarctionand symptomatic peripheral arterial disease. Am J Cardiol 2001;87: 1284-6.
91. The Heart Outcomes Prevention Evaluation Study Investigators.Effects of an angiotensin-converting-enzyme inhibitor, ramipril oncardiovascular events in high-risk patients. N Engl J Med 2000;342: 145-53.
92. Aronow WS, Ahn C, Kronzon I. Effect of beta blockers alone, ofangiotensin-converting enzyme inhibitors alone, and of beta blockersplus angiotensin-converting enzyme inhibitors on new coronaryevents and on congestive heart failure in older persons with healedmyocardial infarcts and asymptomatic left ventricular systolic dysfunction.Am J Cardiol 2001; 88: 1298-300.
93. Kennedy HL, Brooks MM, Barker AH, et al. Beta-blocker therapyin the Cardiac Arrhythmia Suppression Trial. Am J Cardiol 1994;74: 674-80.
94. Aronow WS, Ahn C, Mercando AD, Epstein S, Kronzon I. Effectof propranolol vs. no antiarrhythmic drug on sudden cardiac death,total cardiac death, and total death in patients ≥62 years of age withheart disease, complex ventricular arrhythmias, and left ventricularejection fraction ≥40%. Am J Cardiol 1994; 74: 267-70.
95. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronicheart failure: Metoprolol CR/XL Randomised Intervention Trial inCongestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-7.
96. Flather MD, Shibata MC, Coats AJS, et al. Randomized trial todetermine the effect of nebivolol on mortality and cardiovascularhospital admission in elderly patients with heart failure (SENIORS).Eur Heart J 2005; 26: 215-25.
97. Aronow WS, Ahn C, Kronzon I. Effect of propranolol vs. no propranololon total mortality plus non-fatal myocardial infarction inolder patients with prior myocardial infarction, congestive heartfailure, and left ventricular ejection fraction ≥40% treated with diureticsplus angiotensin-converting-enzyme inhibitors. Am J Cardiol 1997; 80: 207-9.
98. Aronow WS, Frishman WH. Angina in the elderly. In: AronowWS, Fleg JL, Rich MW, eds. Cardiovascular Disease in the Elderly,fourth edition. New York City: Informa Healthcare 2008; pp.269-92.
99. Aronow WS, Ahn C, Mercando AD, Epstein S, Kronzon I. Decreaseof mortality by propranolol in patients with heart disease andcomplex ventricular arrhythmias is more an anti-ischemic than anantiarrhythmic effect. Am J Cardiol 1994; 74: 613-5.
100. Aronow WS. Treatment of atrial fibrillation. Part 1. Cardiol Rev 2008; 16: 181-8.
101. Aronow WS. Treatment of atrial fibrillation and atrial flutter Part 2.Cardiol Rev 2008; 16: 230-9.
102. Aronow WS. The heart and thyroid disease. In: Gambert SR, Ed.Clinics in Geriatric Medicine. Thyroid Disease. Philadelphia: W. B.Saunders Co, 1995; pp. 219-29.
103. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for theevaluation and management of chronic heart failure in the adult:executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines(Committee to Revise the 1995 Guidelines for the Evaluationand Management of Heart Failure). Developed in collaborationwith the International Society for Heart and Lung Transplantation.Endorsed by the Heart Failure Society of America. J Am Coll Cardiol 2001; 38: 2101-13.
104. Agodoa LY, Appel L, Bakris GL, et al. Effect of ramipril vs. amlodipineon renal outcomes in hypertensive nephrosclerosis. A randomizedcontrolled trial. JAMA 2001; 285: 2719-28.
105. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan onrenal and cardiovascular outcomes in patients with type 2 diabetesand nephropathy. N Engl J Med 2001; 345: 861-9.
106. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calciumantagonist vs. a non-calcium antagonist hypertension treatmentstrategy for patients with coronary artery disease. The InternationalVerapamil-Trandolapril Study (INVEST): a randomized controlledtrial. JAMA 2003; 290: 2805-16.
107. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipineor hydrochlorothiazide for hypertension in high-risk patients.N Engl J Med 2008; 359: 2417-28.
108. Smith SC Jr, Allen J, Blair SN, et al. ACC/AHA guidelines forsecondary prevention for patients with coronary and other atheroscleroticvascular disease: 2006 update: endorsed by the NationalHeart, Lung, and Blood Institute. Circulation 2006; 113: 2363-72.
109. Grundy SM, Cleeman JI, Merz CNB, et al. Implications of recentclinical trials for the National Cholesterol Education Program AdultTreatment Panel III guidelines. Circulation 2004; 110: 227-39.
110. Szadkowska I, Stanczyk A, Aronow WS, et al. Statin therapy in theelderly: a review. Arch Gerontol Geriatr 2010; 50(1): 114-8.
111. American Diabetes Association. Standards of medical care forpatients with diabetes mellitus. Diabetes Care 2003; 26 (Suppl 1):533-50.
112. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemiawith macrovascular and microvascular complications of type 2 diabetes(UKPDS 35): prospective observational study. Br Med J 2000; 321: 405-12.
113. Ravipati G, Aronow WS, Ahn C, Sujata K, Saulle LN, Weiss MB. Association of hemoglobin A1c level with the severity of coronaryartery disease in patients with diabetes mellitus. Am J Cardiol 2006; 97: 968-9.
114. Aronow WS, Ahn C, Weiss MB, Babu S. Relation of hemoglobinA1c levels to severity of peripheral arterial disease in patients withdiabetes mellitus. Am J Cardiol 2007; 99: 1468-9.
115. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines forthe Management of Arterial Hypertension. The Task Force for theManagement of Arterial Hypertension of the European Society ofHypertension (ESH) and of the European Society of Cardiology(ESC). J Hypertens 2007; 25: 1105-87.